• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LeMaitre Vascular, Inc. (Amendment)

    1/10/22 2:39:40 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    SC 13G/A 1 lmata5_11022.htm CONESTOGA CAPITAL ADVISORS lmata5_11022.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
    LeMaitre Vascular, Inc.
    (Name of Issuer)
    Common Stock, $0.01 Par Value
    (Title of Class of Securities)
    525558201
    (CUSIP Number)
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 525558201
           
    1
    NAME OF REPORTING PERSON
    Conestoga Capital Advisors, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    23-3072906
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    1,857,183
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    1,948,494
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,948,494
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    8.92%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 525558201
           
    1
    NAME OF REPORTING PERSON
    Conestoga Small Cap Fund
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    22-3865089
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    1,274,721
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    1,274,721
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    1,274,721
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.84%
    12
    TYPE OF REPORTING PERSON
    IV
    CUSIP No.: 525558201
    ITEM 1(a). NAME OF ISSUER:
    LeMaitre Vascular, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    63 Second Avenue
    Burlington, MA 01803
    USA
    ITEM 2(a). NAME OF PERSON FILING:
    Conestoga Capital Advisors, LLC
    Conestoga Small Cap Fund
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    550 E. Swedesford Rd.Ste 120
    Wayne, Pa 19807
    ITEM 2(c). CITIZENSHIP:
    Delaware
    Delaware
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, $0.01 Par Value
    ITEM 2(e). CUSIP NUMBER:
    525558201
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [X]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    As of December 31, 2021, the Reporting Persons Conestoga Capital Advisors indirectly beneficially owned 1,948,494 shares while the Conestoga Small Cap Fund owned 1,274,721 of the 21,838,093 shares of the Issuers Common Stock indirectly beneficially owned by Conestoga Capital Advisors. Such shares of the Issuers Common Stock were directly beneficially owned by the Accounts. The Conestoga Small Cap Fund beneficially owned 5.84% of the Issuers issued and outstanding Common Stock.






    (b) Percent of class:
    Percent of class As of December 31, 2021, the Reporting Persons indirectly beneficially owned 8.92% and 5.84% of the Issuers issued and outstanding Common Stock (based on 21,838,093 shares of the Issuers Common Stock outstanding as of October 27,2021 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4,2021). Such shares of the Issuers Common Stock were directly beneficially owned by the Accounts. The Conestoga Small Cap Fund beneficially owned 5.84% of the Issuers issued and outstanding Common Stock




    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    1,857,183
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    1,948,494
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 525558201
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    January 10 2022
    Conestoga Capital Advisors, LLC
    By:
    /s/ Duane R. D'Orazio
    Name:
    Duane R. D'Orazio
    Title:
    Chief Compliance Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $LMAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

      BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre

      5/5/25 4:39:09 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Financials

    Live finance-specific insights

    See more
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Q4 2024 Financial Results

      BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (NASDAQ:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend of $0.20/share (+25%), and provided guidance. Q4 2024 Financial Results Sales $55.7mm, +14% (+14% organic) vs. Q4 2023Gross margin 69.3%, +121 bpsOp. income $12.9mm, +26%Op. margin 23%Earnings per diluted share $0.49, +30%Cash up $175.8mm sequentially to $299.7mm Grafts (+23%), carotid shunts (+14%) and catheters (+12%) drove Q4 sales growth. APAC sales increased 21%, EMEA 18% and the Americas 12%. XenoSure patches received Chinese cardiac approval in December. The gross margin im

      2/27/25 4:05:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    SEC Filings

    See more
    • SEC Form 10-Q filed by LeMaitre Vascular Inc.

      10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/8/25 4:02:12 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

      5/1/25 4:09:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by LeMaitre Vascular Inc.

      DEFA14A - LEMAITRE VASCULAR INC (0001158895) (Filer)

      4/17/25 10:12:37 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Lemaitre George W sold $8,556,631 worth of shares (100,000 units at $85.57) and exercised 34,619 shares at a strike of $44.64, decreasing direct ownership by 3% to 1,827,003 units (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/20/25 7:11:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Director Ross Bridget A sold $312,000 worth of shares (3,750 units at $83.20) and exercised 3,750 shares at a strike of $30.00 (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/14/25 4:03:49 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Shadan Martha

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      3/31/25 5:34:29 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lemaitre Vascular downgraded by Oppenheimer

      Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

      2/28/25 8:28:09 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Lemaitre Vascular downgraded by Barrington Research

      Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

      2/28/25 7:39:54 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Lemaitre Vascular with a new price target

      Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00

      2/13/25 7:09:15 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

      Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

      3/23/21 8:00:00 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by LeMaitre Vascular Inc.

      SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

      10/22/24 3:49:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/13/24 5:08:02 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

      SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

      2/12/24 3:02:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care